---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210413"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:45:42.049829+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atara biotherapeutics gets FDA alignment on tab-cel BLA resubmission path

## Summary
- Type A meeting with FDA was productive; FDA agreed single-arm study with historical control could support future application.
- Pierre Fabre to submit updated ALLELE study dataset with more patients and longer follow-up as part of resubmission.
- Tabelecleucel is for R/R EBV+ PTLD post solid organ or hematopoietic cell transplant.
- Company expects to provide further regulatory update in Q3 2026.

## SEC filing metadata
- accession: 0001193125-26-210413
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312526210413/0001193125-26-210413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312526210413/atra-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210413
- JSON: https://secwatch.observer/filing/0001193125-26-210413.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.